Limits...
The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma.

Chung FT, Ho MY, Fang YF, Hshieh MH, Wang TY, Kuo CH, Chen HC, Wang CH, Lin SM, Yu CT, Lin HC, Kuo HP - Biomed Res Int (2015)

Bottom Line: Consecutive patients were collected between 2009 and 2012.Their outcomes profiles were analyzed.A prospective design is warranted to confirm this finding.

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic Medicine, Saint Paul's Hospital, Taoyuan 330, Taiwan ; Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, College of Medicine, Taipei 10507, Taiwan ; Department of Internal Medicine, Saint Paul's Hospital, Taoyuan 330, Taiwan ; Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, College of Medicine, Taipei 10507, Taiwan.

ABSTRACT

Objectives: Chemotherapy as first-/second-line treatment in different epidermal growth factor receptor (EGFR) mutation lung adenocarcinoma remains controversial.

Methods: Consecutive patients were collected between 2009 and 2012. Patients were divided into two groups (1st-line chemotherapy: n = 56 and 2nd-line chemotherapy: n = 55). Their outcomes profiles were analyzed.

Results: The overall survival (OS) of all patients (390 versus 662 days, p < 0.0001), as well as both progression-free survival (PFS, 151 versus 252 days, p = 0.0001) and OS (308 versus 704 days, p = 0.0001) of patients with L858R mutation (n = 63), who received 2nd-line chemotherapy, was significantly poor. By univariate and multivariate analysis, 2nd-line chemotherapy, and L858R mutation were significantly related to poor PFS and OS.

Conclusion: In advanced lung adenocarcinoma, L858R mutation and 2nd-line chemotherapy caused a poor outcome. It is a consideration to choice of 1st-line chemotherapy in these subjects. A prospective design is warranted to confirm this finding.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier curve of (a) progression-free survival (PFS) and (b) overall survival (OS) of 1st-line treatment for all patients (n = 111) receiving 1st-line chemotherapy/2nd-line TKIs and 1st-line TKIs/2nd-line chemotherapy.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4644829&req=5

fig1: Kaplan-Meier curve of (a) progression-free survival (PFS) and (b) overall survival (OS) of 1st-line treatment for all patients (n = 111) receiving 1st-line chemotherapy/2nd-line TKIs and 1st-line TKIs/2nd-line chemotherapy.

Mentions: Among all included patients (n = 111), the PFS of patients who received 1st-line chemotherapy/2nd-line TKIs was similar to that of another group (median PSF: 214 versus 188 days, hazard ratio (HR): 0.69; 95% confidence interval (CI): 0.46–1.01; p = 0.06, Figure 1(a)). The OS was significantly different between two groups (1st-line chemotherapy/2nd-line TKIs versus 1st-line TKIs/2nd-line chemotherapy: 662 versus 390 days, HR: 0.34; 95% CI: 0.21–0.55; p < 0.0001, Figure 1(b)).


The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma.

Chung FT, Ho MY, Fang YF, Hshieh MH, Wang TY, Kuo CH, Chen HC, Wang CH, Lin SM, Yu CT, Lin HC, Kuo HP - Biomed Res Int (2015)

Kaplan-Meier curve of (a) progression-free survival (PFS) and (b) overall survival (OS) of 1st-line treatment for all patients (n = 111) receiving 1st-line chemotherapy/2nd-line TKIs and 1st-line TKIs/2nd-line chemotherapy.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4644829&req=5

fig1: Kaplan-Meier curve of (a) progression-free survival (PFS) and (b) overall survival (OS) of 1st-line treatment for all patients (n = 111) receiving 1st-line chemotherapy/2nd-line TKIs and 1st-line TKIs/2nd-line chemotherapy.
Mentions: Among all included patients (n = 111), the PFS of patients who received 1st-line chemotherapy/2nd-line TKIs was similar to that of another group (median PSF: 214 versus 188 days, hazard ratio (HR): 0.69; 95% confidence interval (CI): 0.46–1.01; p = 0.06, Figure 1(a)). The OS was significantly different between two groups (1st-line chemotherapy/2nd-line TKIs versus 1st-line TKIs/2nd-line chemotherapy: 662 versus 390 days, HR: 0.34; 95% CI: 0.21–0.55; p < 0.0001, Figure 1(b)).

Bottom Line: Consecutive patients were collected between 2009 and 2012.Their outcomes profiles were analyzed.A prospective design is warranted to confirm this finding.

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic Medicine, Saint Paul's Hospital, Taoyuan 330, Taiwan ; Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, College of Medicine, Taipei 10507, Taiwan ; Department of Internal Medicine, Saint Paul's Hospital, Taoyuan 330, Taiwan ; Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, College of Medicine, Taipei 10507, Taiwan.

ABSTRACT

Objectives: Chemotherapy as first-/second-line treatment in different epidermal growth factor receptor (EGFR) mutation lung adenocarcinoma remains controversial.

Methods: Consecutive patients were collected between 2009 and 2012. Patients were divided into two groups (1st-line chemotherapy: n = 56 and 2nd-line chemotherapy: n = 55). Their outcomes profiles were analyzed.

Results: The overall survival (OS) of all patients (390 versus 662 days, p < 0.0001), as well as both progression-free survival (PFS, 151 versus 252 days, p = 0.0001) and OS (308 versus 704 days, p = 0.0001) of patients with L858R mutation (n = 63), who received 2nd-line chemotherapy, was significantly poor. By univariate and multivariate analysis, 2nd-line chemotherapy, and L858R mutation were significantly related to poor PFS and OS.

Conclusion: In advanced lung adenocarcinoma, L858R mutation and 2nd-line chemotherapy caused a poor outcome. It is a consideration to choice of 1st-line chemotherapy in these subjects. A prospective design is warranted to confirm this finding.

No MeSH data available.


Related in: MedlinePlus